Estrella Immunopharma Inc. has announced a private placement involving the sale of unregistered securities to a single healthcare-focused institutional investor. The transaction, which is not a public offering and has not been registered under the Securities Act of 1933, includes the sale of pre-funded warrants and PIPE common warrants. These securities may not be resold in the United States without registration or an applicable exemption. The company has agreed to file registration statements to cover the resale of the common stock and shares issuable upon exercise of the warrants, as part of a registration rights agreement with the investor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260105244266) on January 05, 2026, and is solely responsible for the information contained therein.